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SUMMARY OF THESIS*
ABRANTES-LEMOS, Clarice Pires - Pesquisa do anticorpo antitransglutaminase tissular avaliando as interações da transglutaminase
com a fibronectina e comparação com os resultados de dois ensaios comerciais. São Paulo, 2005. (Dissertação de Mestrado - Faculdade
de Medicina da Universidade de São Paulo).
STANDARDIZATION OF ANTI-TISSUE TRANSGLUTAMINASE ANTIBODY DETECTION AND
ASSESSMENT OF TRANSGLUTAMINASE INTERACTIONS WITH FIBRONECTIN. COMPARISON OF
THE RESULTS WITH TWO COMMERCIALLY AVAILABLE ESSAYS
INTRODUCTION: anti-endomysial (EMA) and anti-tissue
transglutaminase (anti-tTg) are the main circulating autoantibodies in patients
with celiac disease. Inasmuch as tissue transglutaminase (tTg) is the target
antigen of EMA, specific assays have been developed to establish the
serological diagnosis of celiac disease. However, published data are
contradictory regarding their superiority over EMA. tTg is a cytoplasm
enzyme, but indirect immunofluorescence reaction (IIF) indicates that EMA
reacts with components of extracellular matrix, particularly with fibronectin.
To date, serological tests have been standardized only with tTg. It is unknown
if the addition of fibronectin to tTg substrate will improve the diagnostic
accuracy. AIMS: 1) to standardize the indirect ELISA for detection of anti-
tTg; 2) to standardize the indirect ELISA for detection of antibodies against
the complex tTg/fibronectin; 3) to compare the results of anti-tTg, anti-
fibronectin and anti-tTg/fibronectin antibody ELISAS of patients with not
treated and treated celiac disease; 4) to compare the results of the in house
indirect ELISA with available commercial kits (with tTg and htTg).
MATERIALS AND METHODS: the casuistic was formed by the sera of
173 patients, including 49 with celiac disease without treatment and 124
controls (chronic diarrhea = 30; inflammatory bowel disease, n = 23;
autoimmune hepatitis type 1 n = 30; treated celiac disease, n = 23; e healthy
individuals, n = 18). EMA was detected by IIF, using sections of human
umbilical cord as substrate. Indirect ELISA was carried out for detection of
reactivity against tTg (from guinea pig liver), fibronectin (recombinant from
human fibroblast) and the complex tTg-fibronectin. The performance of
those essays was compared with that of anti-tTg and anti-htTg kits, purchased
from Inova Diagnostics, Inc, USA. Statistical analysis was performed using
Student t test, Fisher exact test, McNemar test and kappa correlation test
when appropriate. RESULTS: Seropositivity to anti-tTg, antifibronectin and
anti-tTg/fibronectin was observed in, respectively: 46.9%, 51% e 42.9% in
the celiac disease without treatment group; 0%, 13% and 0% in the treated
celiac disease group; 39.1%, 65.2% and 56.5% in the inflammatory bowel
disease group; 20%, 50% and 20% in the autoimmune hepatitis group; 6.7%,
60% and 26.7% in the chronic diarrhea group. No patient among healthy
controls had seropositivity to those aforementioned antibodies. Comparing
the anti-tTg and tTg/fibronectin complex seropositivity in the celiac disease
without treatment group, it was found that the addition of fibronectin to the
tTg substrate did no improved the accuracy of the essay (p = 0.68; relative
risk 1.15; 95% confidence interval = 0.7334-1.803). Comparing EMA titers
with ELISA positivity, it was found that higher seropositivity to anti-tTg,
antifibronectin and anti-tTg/fibronectin complex occurred in sera with EMA
titers equal or higher than 1/1280. There was no relation between age and
the seropositivity of celiac antibodies. Patients with inflammatory bowel
disease had higher rates of seropositivity to anti-tTg (p = 0.029, RR = 6.1
and IC95% = 0.9-41.5) and antifibronectin (p = 0.0097, RR = 6.9 and IC95%
1.0-46.0) when compared with patients with Crohn disease. The concordance
coefficients between the in house ELISA and the anti-htTg (commercial
kit) was: 46.9% (kappa coefficient kappa 0) in the celiac disease without
treatment group; 45.5% (kappa 0) in the treated celiac disease group; 90%
(kappa 0.047, p = 0.786; McNemar, p = 1.0) in the chronic diarrhea group;
56.5% (kappa 0.085, p = 0.412; McNemar, p = 0.021) in the inflammatory
bowel disease group; 83.3% (kappa 0.359, p = 0.033; McNemar, p = 0.375)
in the autoimmune hepatitis group and 100% in the healthy individuals group.
The concordance coefficients between the in house ELISA and the anti-tTg
(guinea pig, commercial kit) was: 46.9% (kappa coefficient 0) in the celiac
disease without treatment group; 54.5% (kappa 0) in the treated celiac disease
group; 90% (kappa 0.047, p = 0.786; McNemar, p = 1.0) in the chronic
diarrhea group; 52.2% (kappa 0.166, p = 0.235; McNemar, p = 0.033) in the
inflammatory bowel disease group; 86.7% (kappa 0.524, p = 0.033;
McNemar, p = 0.635) in the autoimmune hepatitis group and 94% (kappa 0)
in the healthy individuals group. The concordance coefficients between the
two commercial kits varied from 72.7% to 100% in the different groups.
CONCLUSIONS: 1) The in house ELISA was not a good technique for
detecting anti-tTg reactivity due to its low rate of positivity in patients with
celiac disease without treatment and high rate of positivity in EMA negative
control groups; 2) The addition of fibronectin to the substrate tTg did not
improve the diagnostic accuracy of the essay in patients with celiac disease
without treatment; 3) There was no difference in anti-tTg seropositivity rates
between children and adults with celiac disease without treatment; 4) There
was a correlation between the EMA titers and seropositivity to anti-tTg,
detected by the in house ELISA; 5) The seropositivity of all autoantibodies
by ELISA was higher in patients with ulcerative colitis when compared
with Crohn disease; 6) Commercial kits were adequate for the identification
of positive cases (with celiac disease without treatment) and negative cases
among controls; 7) The seronegativity to anti-tTg antibodies by commercial
kit was not systematically followed by the negativation of EMA in patients
with celiac disease. Those findings suggest that anti-tTg ELISA are suitable
for therapeutic monitoring of celiac disease; 8) The standardization of any
ELISA for detection of celiac antibodies should include the comparison
with both available commercial kits and AAE; 9) According to the results of
the current study, the detection of anti-tTg antibodies, using an in house
ELISA with guinea pig liver tTg as substrate, could not be incorporated in
the routine work-up for the serodiagnosis of celiac disease in our hospital.
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